《Table 2 Baseline characteristics》

《Table 2 Baseline characteristics》   提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease》


  1. 获取 高清版本忘记账户?点击这里登录
  1. 下载图表忘记账户?点击这里登录

Several statistically significant differences were found between the characteristics of responders versus those of non-responders to ustekinumab therapy(Table 3).The occurrence of extraintestinal manifestations and steroid use at baseline were negatively associated with response.Also,a higher HBI at treatment initiation was a negative predictor for response(Table 3).Male sex was nearly significantly associated with nonresponse(P=0.05;Table 3).In contrast,the presence of NOD2 mutations was not associated with therapy outcome.The factors with a P value below 0.1-extraintestinal manifestations,steroid use at baseline,HBI at treatment initiation and sex were included in the multivariable logistic regression model.All those factors remained in the optimal model,the odds ratios and P values for which are shown in Table 4.Except for baseline HBI with a P value of 0.071,the other three factors were statistically significantly associated with response,thus confirming the results of the univariate analysis.With an AUC of 91.07%,the model showed excellent predictive qualities.